Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.42 |
| ▸ | FGF1 | P05230 | 2/20 | 0.40 |
| ▸ | FGF2 | P09038 | 2/20 | 0.40 |
| ▸ | VEGFA | P15692 | 2/20 | 0.40 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.40 |
| ▸ | CD209 | Q9NNX6 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30891307 | 0.99 | MMP13 (0.46) | MMP13LGALS8FGF1FGF2VEGFA | |
| SCHEMBL30891273 | 0.99 | MMP13 (0.46) | MMP13LGALS8FGF1FGF2VEGFA | |
| SCHEMBL30391583 | 0.99 | MMP13 (0.46) | MMP13LGALS8FGF1FGF2VEGFA | |
| SCHEMBL30891489 | 0.97 | MMP13 (0.45) | MMP13LGALS8FGF1FGF2VEGFA | |
| SCHEMBL30891488 | 0.97 | MMP13 (0.45) | MMP13LGALS8FGF1FGF2VEGFA | |
| SCHEMBL15130853 | 0.97 | MMP13 (0.47) | MMP13LGALS8FGF1FGF2VEGFA | |
| SCHEMBL25417921 | 0.92 | MMP13 (0.43) | MMP13LGALS8EPHX2MAOB | |
| SCHEMBL30392241 | 0.92 | MMP13 (0.43) | MMP13LGALS8EPHX2MAOB | |
| SCHEMBL30891323 | 0.92 | MMP13 (0.45) | MMP13LGALS8FGF1FGF2VEGFA | |
| SCHEMBL30891371 | 0.92 | MMP13 (0.45) | MMP13LGALS8FGF1FGF2VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4615487-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Merck Sharp & Dohme LLC (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2024102633-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | MERCK SHARP & DOHME LLC (US) | 2024-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021190-A1 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A PENTA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | INSR, GPR119, GLP1R | MMP13 1271/4885LGALS8 615/4885FGF1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.